LOGIN  |  REGISTER
Chimerix
Recursion

Quipt Home Medical on Preliminary List to Join Russell 2000® and 3000® Indexes

May 23, 2023 | Last Trade: US$2.45 0.04 1.66

CINCINNATI, May 23, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is very pleased to announce it is on a preliminary list dated May 19, 2023 issued by FTSE Russell to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023. Updates are provided by the Russell Microcap Index on May 26, June 2, June 9, June 16 and June 23.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28, 2023, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“Being included in the Russell 2000® and 3000® Indexes would be an affirmation of our strategic journey and a testament to the relentless efforts of our team. We remain committed to delivering sustained value to our shareholders and are thrilled by the idea of being included with some of the most forward-thinking companies in the United States, which we believe would considerably increase our visibility and access to the worldwide investment community,” commented Greg Crawford, CEO and Chairman of Quipt. “This inclusion would truly reflect the substantial growth experienced by our company and our evolution as a publicly traded company over the last several years. We are extremely well positioned to continue executing on our growth strategy, which has yielded robust and consistent financial performance, and we look forward to providing our shareholders with updates as we progress on our future vision."

For more information on the Russell 2000® and 3000® Indexes and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Quipt Home Medical Corp.

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. For more information, visit www.ftserussell.com.

Reader Advisories

While the Company is on the May 19, 2023 preliminary list for inclusion on the Russell 2000® and 3000® Indexes, no assurance can be given that it will ultimately be on the final list.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements contained in this press release constitute "forward-looking information" as such term is ‎‎‎‎defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", ‎‎‎‎‎"will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect", "outlook", and similar expressions ‎‎‎as ‎they relate to the Company, including: inclusion on the Russell 2000® and 3000® Indexes and the results of such inclusions; and the Company believing ‎joining the indexes would significantly bolster its visibility and access to the global investment community; are intended to ‎identify forward-looking information. All statements ‎other than statements of ‎‎historical fact may be forward-‎looking information. Such statements reflect the ‎Company's current views and ‎‎intentions with respect to future ‎events, and current information available to the ‎Company, and are subject to ‎‎certain risks, uncertainties and ‎assumptions, including: the Company meeting the inclusion standards of the Russell 2000® and 3000® Indexes. Many factors could ‎cause the actual ‎results, ‎performance or achievements that may be expressed ‎or implied by such forward-looking ‎information to ‎vary from ‎those described herein should one or more of these ‎risks or uncertainties materialize. ‎Examples of such ‎risk factors ‎include, without limitation: risks related to credit, market ‎‎(including equity, ‎commodity, foreign exchange and interest ‎rate), ‎liquidity, operational (including technology ‎and infrastructure), ‎reputational, insurance, strategic, ‎regulatory, legal, ‎environmental, and capital adequacy; the ‎general business ‎and economic conditions in the regions ‎in which the ‎Company operates; the ability of the ‎Company to execute on ‎key priorities, including the successful ‎completion of ‎acquisitions, business retention, and ‎strategic plans and to ‎attract, develop and retain key ‎executives; difficulty ‎integrating newly acquired businesses; ‎the ability to ‎implement business strategies and ‎pursue business opportunities; low profit ‎market segments; ‎disruptions in or ‎attacks (including cyber-attacks) on ‎the Company's information technology, ‎internet, network ‎access or other ‎voice or data communications systems or ‎services; the evolution of various types ‎of fraud or other ‎criminal ‎behavior to which the Company is exposed; the ‎failure of third parties to comply with ‎their obligations to ‎the ‎Company or its affiliates; the impact of new and ‎changes to, or application of, current ‎laws and regulations; ‎‎decline of reimbursement rates; dependence on few ‎payors; possible new drug discoveries; a ‎novel business model; ‎‎dependence on key suppliers; granting of permits ‎and licenses in a highly regulated ‎business; the overall difficult ‎‎litigation environment, including in the U.S.; ‎increased competition; changes in ‎foreign currency rates; increased ‎‎funding costs and market volatility due to ‎market illiquidity and competition for ‎funding; the availability of funds ‎‎and resources to pursue operations; ‎critical accounting estimates and changes ‎to accounting standards, policies, ‎‎and methods used by the Company; ‎the occurrence of natural and unnatural ‎catastrophic events and claims ‎‎resulting from such events; and risks ‎related to COVID-19 including various ‎recommendations, orders and ‎‎measures of governmental authorities to try ‎to limit the pandemic, including travel ‎restrictions, border closures, ‎‎non-essential business closures, quarantines, ‎self-isolations, shelters-in-place and social distancing, ‎disruptions ‎‎to markets, economic activity, financing, ‎supply chains and sales channels, and a deterioration of general ‎‎economic ‎conditions including a possible ‎national or global recession; as well as those risk factors discussed or ‎‎referred to ‎in the Company’s disclosure ‎documents filed with United States Securities and Exchange Commission ‎‎and ‎available at www.sec.gov, and with ‎the securities regulatory authorities in certain provinces of Canada and ‎‎‎available at www.sedar.com. Should any ‎factor affect the Company in an unexpected manner, or should ‎‎‎assumptions underlying the forward-looking ‎information prove incorrect, the actual results or events may differ ‎‎‎materially from the results or events predicted. ‎Any such forward-looking information is expressly qualified in its ‎‎‎entirety by this cautionary statement. Moreover, ‎the Company does not assume responsibility for the accuracy or ‎‎‎completeness of such forward-looking ‎information. The forward-looking information included in this press release ‎‎‎is made as of the date of this press ‎release and the Company undertakes no obligation to publicly update or revise ‎‎‎any forward-looking information, ‎other than as required by applicable law‎.‎

For further information please visit our website at www.Quipthomemedical.com, or contact:‎

Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.‎
‎859-300-6455‎
This email address is being protected from spambots. You need JavaScript enabled to view it.

Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.‎
‎859-300-6455‎
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB